Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants.

Publication Detail

The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.

Davide Bruno; Nunzio Pomara; Jay Nierenberg; James C Ritchie; Michael W Lutz; Henrik Zetterberg; Kaj Blennow (Profiled Author: Blennow, Kaj)

Nathan Kline Institute, Orangeburg, NY 10962, USA. d.bruno@nki.rfmh.org
Experimental gerontology 2012;47(5):347-52.

PubMed

Abstract

Neurofilament light (NFL) proteins in cerebrospinal fluid (CSF) are a marker of neuronal damage, especially subcortical axonal injury and white matter disease. Subjects with Alzheimer's disease (AD) have shown elevated levels of CSF NFL as compared to controls. However, the presence of the APOE ε4 allele, an established risk factor for AD, was not found to associate with higher CSF NFL concentrations. We examined whether TOMM40 variants, which have been reported to influence age of onset of AD and are in linkage disequilibrium with APOE, have an effect on CSF NFL levels, in 47 healthy, cognitively intact individuals with or without APOE ε4. Our results show that the presence of APOE ε4 alone does not affect CSF NFL levels significantly; however APOE and TOMM40 appear to interact. Subjects with APOE ε4 have higher CSF NFL levels than non-ε4 carriers, only when they do not carry a short poly-T variant of TOMM40, which is associated with later age of onset of AD, and may act as protective against the dose effect of ε4.

Scientific Context

This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.

Related Grants

1.

Mayeux, Richard

Epidemiology of Dementia In An Urban Community

1 February 1989 - 30 June 2009
NATIONAL INSTITUTE ON AGING
Total Funding: $ 40,531,208
2.

TANZI, RUDOLPH EMILE

Characterization of Alzheimer's Mutations in ADAM10.

30 September 2012 - 31 August 2017
NATIONAL INSTITUTE ON AGING
Total Funding: $ 345,936
3.

Goate, Alison M

The Role of Cholesterol in Alzheimer's Disease

1 July 2005 - 30 June 2008
FOGARTY INTERNATIONAL CENTER
Total Funding: $ 117,923

Related Publications

1.
2010

A D Roses; M W Lutz; H Amrine-Madsen; A M Saunders; D G Crenshaw; S S Sundseth; M J Huentelman; K A Welsh-Bohmer; E M Reiman

A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease.
The pharmacogenomics journal 2010;10(5):375-84.
2.
2008

Lynn M Bekris; Steven P Millard; Nichole M Galloway; Simona Vuletic; John J Albers; Ge Li; Douglas R Galasko; Charles DeCarli; Martin R Farlow; Chris M Clark; et al.

Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels.
Journal of Alzheimer's disease : JAD 2008;13(3):255-66.
3.
2004

Benjamin Tycko; Joseph H Lee; Alejandra Ciappa; Anjana Saxena; Chi-Ming Li; Lin Feng; Alex Arriaga; Yaakov Stern; Rafael Lantigua; Neil Shachter; et al.

APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals.
Archives of neurology 2004;61(9):1434-9.